RB

Radheshyam Bhati

Active Director Director DIN 10645945
DIN 10645945 First appointment Jun 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Radheshyam Bhati

Data last updated:

Radheshyam Bhati is a Director at Ambumed Pharma Private Limited (since 2024). The company operates in Pharma.

DIN 10645945
Primary Designation Director
Industry Pharma
First Appointment 11 Jun 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ambumed Pharma Private Limited U21001TS2024PTC183695
Director11 Jun 20242024Active

Directorship timeline

Open interactive timeline →
Ambumed Pharma Private Limited
Premium access

Shareholding and investment profile for Radheshyam Bhati

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Radheshyam Bhati

Radheshyam Bhati currently holds 1 directorship: Ambumed Pharma Private Limited (Director, since 11 Jun 2024).

Radheshyam Bhati was first appointed on 11 Jun 2024 as Director at Ambumed Pharma Private Limited.

The current boards of Radheshyam Bhati's companies include Ashok Bhati (Ambumed Pharma Private Limited), Dinesh Bhati (Ambumed Pharma Private Limited), Mahesh Kumar Toshniwal (Ambumed Pharma Private Limited), Manoj Kumar Bhati (Ambumed Pharma Private Limited), Pradeep Kumar Sharma (Ambumed Pharma Private Limited), Ram Kumar Bhati (Ambumed Pharma Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available